Upside:
-ALLO +66% (reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL)
-RVMD +34% (Daraxonrasib demonstrates overall survival benefit in Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer)
-ALMU +27% (awarded >$4M in U.S. Government contracts for quantum and datacom scaling)
-SYRE +25% (SPY001 met primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score)
-ERAS +20% (momentum)
-IDYA +13% (Phase 2/3 OptimUM-02 met the primary endpoint in first-line HLA-A*02:01-negative metastatic uveal melanoma)
-LEG +8.8% (to be acquired by Somnigroup International in an all-stock transaction valued at ~$2.5B)
-TLX +5.5% (announces Radiopharma collaboration agreement with Regeneron under which the co. will receive $40M upfront and $2.1B in possible additional payments)
-SWMR +4.1% (Boutique Firm Initiates SWMR with Buy, price target: $60)
-ON +3.8% (Tier1 firm Raised ON to Buy from Neutral, price target: $85 from $70)
-AVT +3.3% (Truist Raised AVT to Buy from Hold, price target: $80)
-DIOD +2.9% (Truist Raised DIOD to Buy from Hold, price target: $98)
-MRVL +2.4% (B. Riley Securities, Inc Reiterates MRVL with Buy, price target: $156 from $135)
Downside:
-REPL -64% (confirms RP1 melanoma BLA gets FDA complete response letter; Company to cut jobs and scale back U.S. manufacturing)
-PLCE -17% (earnings)
-GS -4.7% (earnings)
-GFL -4.0% (SES.CA to be acquired by GFL at $24.75/shr)
-FAST -3.0% (earnings, guidance)
-NXPI -2.6% (Tier1 firm Cuts NXPI to Neutral from Buy, price target: $230 from $245)
None.